The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab.
Mehdi Hamadani
No relevant relationships to disclose
Andres Forero
Research Funding - MedImmune
Thomas J. Kipps
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Michelle A. Fanale
Research Funding - MedImmune
Antonio Cuneo
Research Funding - MedImmune
Jaime Perez de Oteyza
Research Funding - MedImmune
Douglas Gladstone
Honoraria - MedImmune
Research Funding - MedImmune
Expert Testimony - AstraZeneca
Trishna Goswami
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Research Funding - MedImmune
Ramy A. Ibrahim
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Meina Liang
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Steven Eck
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Nairouz Elgeioushi
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Ronald Herbst
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Bruce D. Cheson
Research Funding - MedImmune